GLP-3 (Retatrutide)

CAS

2381089-83-2

Dose

5mg per vial

Formula

C₂₁₄H₃₃₃N₅₀O₆₅

4731.5 g/mol

Batch

PX-2026-0142

Purity

99.1%

Triple-agonist peptide (GLP-1 / GIP / Glucagon) under active clinical investigation for metabolic research.

Per vial · CAD

CAD $129

Selected

5mg per vial

Choose dose

Order this vial

Lyophilized · ambient-stable · In stock

Batch PX-2026-0142 →

Research use only. Not for diagnostic, therapeutic, or human-consumption use.

Buying in volume? US and UK wholesale handled by direct contact — custom rates by monthly order volume.

Apply to the wholesale program

Production COA

Per batch

Verification

3rd party

Form

Lyophilized

Current batch

The chromatogram for this vial.

Full batch report

Batch PX-2026-0142 · HPLC trace

GLP-3 (Retatrutide)

Purity

99.1%

Produced

2026-03-28

Verified

2026-04-02

Signed by Independent third-party lab · 2026-04-02Hover the peaks to inspect retention times

Overview

About the compound.

Retatrutide is a triple-receptor agonist engaging GLP-1, GIP, and glucagon pathways simultaneously. Phase 2 obesity results were published in the New England Journal of Medicine (Jastreboff et al., 2023); the TRIUMPH Phase 3 program is currently enrolling. Production batch came back at 99.1% purity by HPLC.

Research contexts

Metabolic researchGlucose regulation pathwaysEnergy expenditure modeling

Cited research

Batch history